litlas
ログインアカウント作成

Andrew K. Joe

2002–2025 年に発表

27
論文数
19,901
被引用数
23
h 指数
24
i10 指数

被引用数

Andrew K. Joe の年別被引用数1945 年: 被引用 1 件2002 年: 被引用 2 件2003 年: 被引用 12 件2004 年: 被引用 13 件2005 年: 被引用 20 件2006 年: 被引用 11 件2007 年: 被引用 24 件2008 年: 被引用 41 件2009 年: 被引用 51 件2010 年: 被引用 49 件2011 年: 被引用 67 件2012 年: 被引用 157 件2013 年: 被引用 211 件2014 年: 被引用 201 件2015 年: 被引用 151 件2016 年: 被引用 109 件2017 年: 被引用 141 件2018 年: 被引用 314 件2019 年: 被引用 918 件2020 年: 被引用 1,169 件2021 年: 被引用 1,281 件2022 年: 被引用 1,005 件2023 年: 被引用 675 件2024 年: 被引用 877 件2025 年: 被引用 461 件2026 年: 被引用 11 件1946〜2001 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,179 件、この内訳の 27.3%中国: 引用元論文 1,567 件、この内訳の 13.5%イタリア: 引用元論文 716 件、この内訳の 6.2%イギリス: 引用元論文 611 件、この内訳の 5.2%ドイツ: 引用元論文 554 件、この内訳の 4.8%フランス: 引用元論文 513 件、この内訳の 4.4%日本: 引用元論文 471 件、この内訳の 4%スペイン: 引用元論文 414 件、この内訳の 3.6%オーストラリア: 引用元論文 323 件、この内訳の 2.8%カナダ: 引用元論文 314 件、この内訳の 2.7%オランダ: 引用元論文 285 件、この内訳の 2.4%韓国: 引用元論文 250 件、この内訳の 2.1%
0%27.3%その他 21%

機関

分野

  • Medicine67.8%
  • Biochemistry, Genetics and Molecular Biology25.1%
  • Immunology and Microbiology4.7%
  • Engineering0.5%
  • Computer Science0.5%
  • Neuroscience0.3%
  • その他1.1%

トピック

  • Cancer Immunotherapy and Biomarkers14.3%
  • Cancer Genomics and Diagnostics5.2%
  • Immunotherapy and Immune Responses4.3%
  • Genetic factors in colorectal cancer3.8%
  • Melanoma and MAPK Pathways3.8%
  • Pancreatic and Hepatic Oncology Research3.1%
  • その他65.5%

共著者

全論文

検索で開く
  1. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

    著者: Dung T. Le, Jennifer N. Durham, Kellie N. Smith, Hao Wang, Bjarne R. Bartlett, Laveet K. Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon Luber, Fay Wong, Nilofer S. Azad, Agnieszka A. Rucki, Dan Laheru, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Tim F. Greten, Austin G. Duffy, Kristen K. Ciombor, Aleksandra Eyring, Bao H. Lam, Andrew K. Joe, Soonmo Peter Kang, Matthias Holdhoff, Ludmila Danilova, Leslie Cope, Christian F. Meyer, Shibin Zhou, Richard M. Goldberg, Deborah K. Armstrong, Katherine M. Bever, Amanda N. Fader, Janis M. Taube, Franck Housseau, David Spetzler, Nianqing Xiao, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, James R. Eshleman, Bert Vogelstein, Robert A. Anders, Luis A. Díaz - Science 2017 被引用: 6,766

  2. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

    著者: Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto, Anna Maria Di Giacomo, Ana De Jesus‐Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R. Hansen, Sarina A. Piha‐Paul, Toshihiko Doi, Bo Gao, Hyun Cheol Chung, José A. López-Martín, Yung-Jue Bang, Ronnie Shapira Frommer, Manisha H. Shah, Razi Ghori, Andrew K. Joe, Scott K. Pruitt, Luis A. Díaz - Journal of Clinical Oncology 2019 被引用: 2,963

  3. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

    著者: Răzvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer H. Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn, Chunsheng Zhang, Jared Lunceford, Andrew K. Joe, Jonathan D. Cheng, Andrea L. Webber, Nageatte Ibrahim, Elizabeth R. Plimack, Patrick A. Ott, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan, Joanne E. Tomassini, Andrey Loboda, David R. Kaufman - Science 2018 被引用: 2,380

  4. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

    著者: Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul, Albiruni R. Abdul Razak, Jaafar Bennouna, Jean‐Charles Soria, Hope S. Rugo, Roger B. Cohen, Bert H. O’Neil, Janice M. Mehnert, Juanita Lopez, Toshihiko Doi, Emilie M.J. van Brummelen, Răzvan Cristescu, Ping Yang, Kenneth Emancipator, Karen Stein, Mark Ayers, Andrew K. Joe, Jared Lunceford - Journal of Clinical Oncology 2018 被引用: 992

  5. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    著者: Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, René González, Anna C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Peter Hersey, Richard Kefford, Donald P. Lawrence, Igor Puzanov, Karl D. Lewis, Ravi K. Amaravadi, Bartosz Chmielowski, H. Jeffrey Lawrence, Yu Shyr, Fei Ye, Jiang Li, K. B. Nolop, Richard J. Lee, Andrew K. Joe, Antoni Ribas - New England Journal of Medicine 2012 被引用: 2,148

  6. Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.

    著者: Alison M. Schram, Kōichi Goto, Dong‐Wan Kim, Patricia Martín-Romano, Sai‐Hong Ignatius Ou, Grainne M. O’Kane, Eileen M. O’Reilly, Kumiko Umemoto, M. Duruisseaux, Cindy Neuzillet, Frans L. Opdam, Jordi Rodon Ahnert, Misako Nagasaka, Benjamin A. Weinberg, Teresa Macarulla, Andrew K. Joe, Jim Ford, Viktoriya Stalbovskaya, Ernesto Wasserman, Alexander Drilon - Journal of Clinical Oncology 2022 被引用: 66

  7. Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

    著者: Alison M. Schram, Kōichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M. O’Reilly, Sai‐Hong Ignatius Ou, Jordi Rodón, Sun Young Rha, Kazumi Nishino, M. Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V. Liu, Benjamin A. Weinberg, James M. Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld, Tanios Bekaii‐Saab, Grainne M. O’Kane, Frans L. Opdam, Kim A. Reiss, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, Alexander Drilon - New England Journal of Medicine 2025 被引用: 104

  8. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

    著者: Dong‐Wan Kim, Alison M. Schram, Antoine Hollebecque, Kazumi Nishino, Teresa Macarulla, Sun Young Rha, M. Duruisseaux, Stephen V. Liu, Mohammed Najeeb Al Hallak, Kumiko Umemoto, Claas Wesseler, James M. Cleary, Christoph Springfeld, Cindy Neuzillet, Andrew K. Joe, Shekeab Jauhari, Jim Ford, Kōichi Goto - Future Oncology 2024 被引用: 43

  9. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

    著者: Fei Su, Amaya Virós, Carla Milagre, Kerstin Trunzer, Gideon Bollag, Olivia Spleiss, Jorge S. Reis‐Filho, Xiangju Kong, Richard C. Koya, Keith T. Flaherty, Paul B. Chapman, Min Jung Kim, Robert Hayward, Matthew J. Martin, Hong Yang, Qiongqing Wang, Holly Hilton, Julie S. Hang, Johannes Noé, Maryou Lambros, Felipe C. Geyer, Nathalie Dhomen, Ion Niculescu‐Duvaz, Alfonso Zambon, Dan Niculescu‐Duvaz, Natasha Preece, Lídia Robert, Nicholas Otte, Stephen Mok, Damien Kee, Yan Ma, Chao Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Hoa Nguyen, Mark Kockx, Luc Andries, Brian Lestini, K. B. Nolop, Richard J. Lee, Andrew K. Joe, James L. Troy, René González, Thomas E. Hutson, Igor Puzanov, Bartosz Chmielowski, Caroline J. Springer, Grant A. McArthur, Jeffrey A. Sosman, Roger S. Lo, Antoni Ribas, Richard Marais - New England Journal of Medicine 2012 被引用: 1,028

  10. Oncogene Addiction

    著者: I. Bernard Weinstein, Andrew K. Joe - Cancer Research 2008 被引用: 780

  11. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

    著者: I. Bernard Weinstein, Andrew K. Joe - Nature Clinical Practice Oncology 2006 被引用: 707

  12. Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.

    著者: Jérôme Fayette, Florian Clatot, Irene Braña, Esma Saâda, Carla M.L.- van Herpen, Thibault Mazard, Cesar A. Perez, Josep Tabernero, Christophe Le Tourneau, Antoine Hollebecque, V. Arrazubi Arrula, Elisa Fontana, Shumei Kato, Assuntina G. Sacco, Amir Harandi, Jan Paul de Boer, Jessica A. Hellyer, Eduardo Pennella, Andrew K. Joe, Amaury Daste - Journal of Clinical Oncology 2024 被引用: 18

  13. Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

    著者: Kerstin Trunzer, Anna C. Pavlick, Lynn M. Schuchter, René González, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Kevin B. Kim, Jeffrey S. Weber, Peter Hersey, Georgina V. Long, Donald P. Lawrence, Patrick A. Ott, Ravi K. Amaravadi, Karl D. Lewis, Igor Puzanov, Roger S. Lo, Astrid Koehler, Mark Kockx, Olivia Spleiss, Annette Schell-Steven, Houston Gilbert, Louise Cockey, Gideon Bollag, Richard J. Lee, Andrew K. Joe, Jeffrey A. Sosman, Antoni Ribas - Journal of Clinical Oncology 2013 被引用: 363

  14. Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.

    著者: Alison M. Schram, Eileen M. O’Reilly, Grainne M. O’Kane, Kōichi Goto, Dong‐Wan Kim, Cindy Neuzillet, Patricia Martín-Romano, M. Duruisseaux, Misako Nagasaka, Jordi Rodón, Benjamin A. Weinberg, K. Umemoto, Sai‐Hong Ignatius Ou, Teresa Macarulla, Christelle de la Fouchardière, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Alexander Drilon - Journal of Clinical Oncology 2021 被引用: 54

  15. Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

    著者: Mario E. Lacouture, Madeleine Duvic, Axel Hauschild, Víctor G. Prieto, Caroline Robert, Dirk Schadendorf, Caroline C. Kim, Christopher McCormack, Patricia L. Myskowski, Olivia Spleiss, Kerstin Trunzer, Fei Su, B. Nelson, K. B. Nolop, Joseph F. Grippo, Richard J. Lee, Matthew J. Klimek, James L. Troy, Andrew K. Joe - The Oncologist 2013 被引用: 215

  16. (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells

    著者: Seiji Adachi, Tomokazu Nagao, Shing Shun Tony To, Andrew K. Joe, Masahito Shimizu, Rie Matsushima‐Nishiwaki, Osamu Kozawa, Hisataka Moriwaki, Frederick R. Maxfield, I. Bernard Weinstein - Carcinogenesis 2008 被引用: 86

  17. Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).

    著者: Mariana Brandão, Jon Zugazagoitia, Anne‐Marie C. Dingemans, M. Duruisseaux, Pauline Parent, Óscar Juan, Alexander I. Spira, Cécile Vicier, Gérard Zalcman, B. Barasa, Chris Yan, Petra Doze, Andrew K. Joe, Gianluca Laus, Enriqueta Felip - Journal of Clinical Oncology 2024 被引用: 5

  18. Comparing Genetic Ancestry and Self-Described Race in African Americans Born in the United States and in Africa

    著者: Rona Yaeger, Alexa Avila-Bront, Kazeem Abdul, Patricia C. Nolan, Victor R. Grann, Mark Birchette, Shweta Choudhry, Esteban G. Burchard, Kenneth B. Beckman, Prakash Gorroochurn, Elad Ziv, Nathan S. Consedine, Andrew K. Joe - Cancer Epidemiology Biomarkers & Prevention 2008 被引用: 136

  19. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

    著者: A. Ribas, K. B. Kim, Lynn M. Schuchter, R. Gonzalez, Anne C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Keith T. Flaherty, Stergios J. Moschos, Donald P. Lawrence, Peter Hersey, Richard Kefford, Bartosz Chmielowski, Igor Puzanov, J. Li, K. B. Nolop, R. J. Lee, Andrew K. Joe, J. A. Sosman - Journal of Clinical Oncology 2011 被引用: 132

  20. 411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial

    著者: C. Le Tourneau, J. Fayette, C. Even, Assuntina G. Sacco, Amaury Daste, Irene Braña, C. van Herpen, Thibault Mazard, S. Henry, Michael Saerens, Andrew K. Joe, Eduardo Pennella, Y-M. Shen, K. Bol, Lokesh Jain, Marta M. Ferrer, Richard de Leeuw, Antoine Hollebecque - Annals of Oncology 2024 被引用: 9

  21. Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.

    著者: Chrisann Kyi, Marloes van Dongen, Sylvie Rottey, Ignacio Melero, Diana Mittag, Dane Gouveia, Kees Bol, Chris Yan, Andrew K. Joe, Gianluca Laus, Víctor Moreno - Journal of Clinical Oncology 2024 被引用: 7

  22. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines.

    著者: Andrew K. Joe, Hui Liu, Masumi Suzui, Muhammet E Vural, Danhua Xiao, I B Weinstein - 2002 被引用: 455

  23. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.

    著者: Paul B. Chapman, Axel Hauschild, Caroline Robert, James Larkin, John B.A.G. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo A. Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Claus Garbe, Michele Maio, K. B. Nolop, Betty J Nelson, Andrew K. Joe, Keith T. Flaherty, Grant A. McArthur - Journal of Clinical Oncology 2012 被引用: 140

  24. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.

    著者: Luis A. Díaz, Aurélien Marabelle, Jean‐Pierre Delord, Ronnie Shapira‐Frommer, Ravit Geva, Nir Peled, Tae Won Kim, Thierry André, Eric Van Cutsem, Rosine Guimbaud, Dirk Jaeger, Elena Élez, Takayuki Yoshino, Andrew K. Joe, Baohoang Lam, Christine K. Gause, Scott K. Pruitt, Soonmo Peter Kang, Dung T. Le - Journal of Clinical Oncology 2017 被引用: 124